169 related articles for article (PubMed ID: 22152489)
1. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review.
Cruz Fernández-Espartero M; Pérez-Zafrilla B; Naranjo A; Esteban C; Ortiz AM; Gómez-Reino JJ; Carmona L;
Semin Arthritis Rheum; 2011 Dec; 41(3):524-33. PubMed ID: 22152489
[TBL] [Abstract][Full Text] [Related]
2. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review.
Fernández-Espartero MC; Pérez-Zafrilla B; Naranjo A; Esteban C; Ortiz AM; Gómez-Reino JJ; Carmona L;
Semin Arthritis Rheum; 2011 Feb; 40(4):330-7. PubMed ID: 20864146
[TBL] [Abstract][Full Text] [Related]
3. Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy.
Peña-Sagredo JL; Fariñas MC; Perez-Zafrilla B; Cruz-Valenciano A; Crespo M; Joven-Ibañez B; Riera E; Manero-Ruiz FJ; Chalmeta I; Hernández MV; Rodríguez-Gómez M; Maíz O; López R; Cobo T; Pita J; Carmona L; Gonzalez-Gay MA;
Clin Exp Rheumatol; 2009; 27(6):920-5. PubMed ID: 20149306
[TBL] [Abstract][Full Text] [Related]
4. Cancer in patients with rheumatic diseases exposed to TNF antagonists.
Carmona L; Abasolo L; Descalzo MA; Pérez-Zafrilla B; Sellas A; de Abajo F; Gomez-Reino JJ; ;
Semin Arthritis Rheum; 2011 Aug; 41(1):71-80. PubMed ID: 21093020
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.
Hernández MV; Sanmartí R; Cañete JD; Descalzo MA; Alsina M; Carmona L; Gomez-Reino JJ;
Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2024-31. PubMed ID: 23926075
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists.
García-Doval I; Pérez-Zafrilla B; Descalzo MA; Roselló R; Hernández MV; Gómez-Reino JJ; Carmona L;
Ann Rheum Dis; 2010 Oct; 69(10):1751-5. PubMed ID: 20551153
[TBL] [Abstract][Full Text] [Related]
8. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
Gómez-Reino JJ; Carmona L; Angel Descalzo M;
Arthritis Rheum; 2007 Jun; 57(5):756-61. PubMed ID: 17530674
[TBL] [Abstract][Full Text] [Related]
9. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0.
Carmona L; Descalzo MA; Ruiz-Montesinos D; Manero-Ruiz FJ; Perez-Pampin E; Gomez-Reino JJ;
Rheumatology (Oxford); 2011 Jan; 50(1):85-92. PubMed ID: 20601654
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review.
Maneiro JR; Salgado E; Gomez-Reino JJ; Carmona L;
Semin Arthritis Rheum; 2012 Aug; 42(1):89-103. PubMed ID: 22387045
[TBL] [Abstract][Full Text] [Related]
11. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry.
Pérez-Sola MJ; Torre-Cisneros J; Pérez-Zafrilla B; Carmona L; Descalzo MA; Gómez-Reino JJ;
Med Clin (Barc); 2011 Nov; 137(12):533-40. PubMed ID: 21514606
[TBL] [Abstract][Full Text] [Related]
12. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience.
Peña-Sagredo JL; Hernández MV; Fernandez-Llanio N; Giménez-Ubeda E; Muñoz-Fernandez S; Ortiz A; Gonzalez-Gay MA; Fariñas MC;
Clin Exp Rheumatol; 2008; 26(5):854-9. PubMed ID: 19032819
[TBL] [Abstract][Full Text] [Related]
13. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0.
Gómez-Reino JJ; Rodríguez-Lozano C; Campos-Fernández C; Montoro M; Descalzo MÁ; Carmona L;
Ann Rheum Dis; 2012 Mar; 71(3):382-5. PubMed ID: 21998116
[TBL] [Abstract][Full Text] [Related]
14. Retention of golimumab treatment following discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry.
Pombo-Suárez M; Sanchez-Piedra C; Ruiz-Montesino D; Diaz-Torne C; Jovaní V; Cea-Calvo L; Castrejón I
Musculoskeletal Care; 2022 Jun; 20(2):403-407. PubMed ID: 34668303
[No Abstract] [Full Text] [Related]
15. BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries.
Carmona L; de la Vega M; Ranza R; Casado G; Titton DC; Descalzo MÁ; Gómez-Reino J
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-163-7. PubMed ID: 25365109
[TBL] [Abstract][Full Text] [Related]
16. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
[TBL] [Abstract][Full Text] [Related]
17. Objectives and methodology of BIOBADASER phase iii.
Sanchez-Piedra C; Hernández Miguel MV; Manero J; Roselló R; Sánchez-Costa JT; Rodríguez-Lozano C; Campos C; Cuende E; Fernández-Lopez JC; Bustabad S; Martín Domenech R; Pérez-Pampín E; Del Pino-Montes J; Millan-Arciniegas AM; Díaz-González F; Gómez-Reino JJ;
Reumatol Clin (Engl Ed); 2019; 15(4):229-236. PubMed ID: 28935290
[TBL] [Abstract][Full Text] [Related]
18. Demyelination and inhibition of tumor necrosis factor (TNF).
Magnano MD; Robinson WH; Genovese MC
Clin Exp Rheumatol; 2004; 22(5 Suppl 35):S134-40. PubMed ID: 15552527
[TBL] [Abstract][Full Text] [Related]
19. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.
Seror R; Richez C; Sordet C; Rist S; Gossec L; Direz G; Houvenagel E; Berthelot JM; Pagnoux C; Dernis E; Melac-Ducamp S; Bouvard B; Asquier C; Martin A; Puechal X; Mariette X;
Rheumatology (Oxford); 2013 May; 52(5):868-74. PubMed ID: 23287362
[TBL] [Abstract][Full Text] [Related]
20. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry.
Busquets N; Tomero E; Descalzo MÁ; Ponce A; Ortiz-Santamaría V; Surís X; Carmona L; Gómez-Reino JJ;
Rheumatology (Oxford); 2011 Nov; 50(11):1999-2004. PubMed ID: 21856725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
